Idera Pharmaceuticals Inc (IDRA)

[terry hallinan]

Idera Pharmaceuticals, Inc. (Idera) (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases, today announced the acceptance of three abstracts related to the ILLUMINATE clinical development program at the upcoming ASCO meeting being held June 1-5, 2018 in Chicago. The abstracts include a clinical data update from the ILLUMINATE 204 trial in anti-PD-1 refractory melanoma provided by lead investigator Adi Diab, MD from the University of Texas MD Anderson Cancer Center; this abstract will also be featured in a poster discussion session at the meeting.

PR'd above.

Love to be at ASCO but my traveling days are largely behind me.

Don't know how many are aware but the poster sessions can be more successful than many dreary speeches to tired partiers.

Of course there is a rare silver-tongued orator that lights a forest fire from the podium but kindly note I underlined rare.

Best, Terry